Optimal Timing and Site Selection for Minimally Invasive Surgery in Intracerebral Hemorrhage
By
Yun-Xiang Zhou
Guo-Bin Zhang
April 1, 2026
Clinical Scorecard: Optimal Timing and Site Selection for Minimally Invasive Surgery in Intracerebral Hemorrhage
At a Glance
Category Detail
Condition Supratentorial Intracerebral Hemorrhage (ICH) Key Mechanisms Minimally invasive surgery (MIS) to evacuate hematoma aiming to reduce clot volume and improve outcomes Target Population Patients with supratentorial ICH, including lobar and deep hemorrhages Care Setting Acute neurosurgical care, ideally within 24 hours of hemorrhage onset
Key Highlights
MIND trial achieved excellent technical results with most patients having residual clot volume ≤15 mL after MIS. Overall MIND trial showed no mortality or disability benefit at 180 days, possibly due to late timing of surgery and predominance of deep hemorrhages. Earlier intervention (within 24 hours) and lobar hemorrhage location may be associated with better functional outcomes based on prior trials. Guideline-Based Recommendations
Diagnosis
Identify hematoma location (lobar vs deep) via imaging to guide surgical decision-making. Management
Consider minimally invasive surgery for hematoma evacuation, aiming for residual clot volume ≤15 mL. Prioritize early surgical intervention, ideally within 24 hours of symptom onset, especially for lobar hemorrhages. Monitoring & Follow-up
Monitor residual clot volume post-surgery to assess technical success. Assess functional outcomes longitudinally up to at least 180 days. Risks
Delayed surgery (>24 hours) may reduce potential benefits of MIS. Deep hemorrhages may be less responsive to MIS and technically more challenging. Patient & Prescribing Data
Patients with supratentorial ICH undergoing MIS, predominantly with deep hemorrhages in MIND trial.
Early evacuation and lobar location may improve functional outcomes; technical success defined as residual clot ≤15 mL is achievable.
Clinical Best Practices
Aim for early surgical intervention within 24 hours of ICH onset when feasible. Stratify patients by hematoma location (lobar vs deep) to tailor surgical approach and expectations. Achieve maximal clot evacuation to residual volume ≤15 mL to optimize potential benefits. Use combined analysis of timing, location, and surgical success to guide patient selection and future trial designs. References
